A
Annovis Bio, Inc. (ANVS)
2.03
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
2.03
0.00 (0.00%)
Annovis Bio, Inc., klinik bosqichdagi dori platformasi kompaniyasi, Qo'shma Shtatlarda neyrodegenerativ kasalliklarni davolash uchun dorilarni ishlab chiqadi. Kompaniyaning yetakchi mahsulot nomzodi Buntanetap bo'lib, u Altsgeymer kasalligini davolash uchun 2/3-bosqichda, shuningdek, Parkinson kasalligini davolash uchun 3-bosqichda; va Lewy tana demensiyasini davolash uchun 2-bosqich klinik sinovda. U, shuningdek, travmatik miya shikastlanishi va/yoki insultni davolash uchun 2 va 3-bosqich klinik sinovlarda bo'lgan ANVS405; va Altsgeymer kasalligi va demensiyaning keyingi bosqichlarida kognitiv qobiliyatni oshirish uchun ishlab chiqilgan 1-bosqich klinik sinovni yakunlagan ANVS301ni ishlab chiqadi. Annovis Bio, Inc. 2008-yilda ro'yxatga olingan va shtab-kvartirasi Malvern, Pensilvaniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research & Development |
| Dr. Maria L. Maccecchini Ph.D. | Founder, CEO, President & Executive Director |
| Mr. Mark Patrick Guerin C.M.A., CPA, CFM | Chief Financial Officer |
| Ms. Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-16 | 8-K | tm268976d1_8k.htm |
| 2026-03-13 | 10-K | anvs-20251231x10k.htm |
| 2026-01-28 | 8-K | tm264292d1_8k.htm |
| 2025-11-13 | 8-K | anvs-20251112x8k.htm |
| 2025-11-12 | 10-Q | anvs-20250930x10q.htm |
| 2025-10-28 | 8-K | tm2529544d2_8k.htm |
| 2025-10-14 | 8-K | tm2528502d2_8k.htm |
| 2025-09-29 | 8-K | tm2527170d1_8k.htm |
| 2025-08-15 | 8-K | tm2523187d1_8k.htm |
| 2025-08-12 | 10-Q | anvs-20250630x10q.htm |